个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wang, Wenxian[1] * ; Wang, Qian[2] ; Xu, Chunwei[3,4] ; Li, Ziming[5] ; Song, Zhengbo[1] ; Zhang, Yongchang[6] ; Cai, Xiuyu[7] ; Zhang, Shirong[8] ; Lian, Bin[9] ; Li, Wen[10] ; Liu, Anwen[11] ; Zhan, Ping[4] ; Liu, Hongbing[4] ; Lv, Tangfeng[4] ; Miao, Liyun[12] ; Min, Lingfeng[13] ; Chen, Yu[14,15] ; Yuan, Jingping[16] ; Wang, Feng[17] ; Jiang, Zhansheng[18] ; Lin, Gen[14,15] ; Pu, Xingxiang[19,20] ; Rao, Chuangzhou[21] ; Lv, Dongqing[22] ; Yu, Zongyang[23] ; Li, Xiaoyan[24] ; Tang, Chuanhao[25] ; Zhou, Chengzhi[26] ; Xie, Congying[27] ; Zhang, Junping[28] ; Guo, Hui[29] ; Chu, Qian[30] ; Meng, Rui[31] ; Wu, Jingxun[32] ; Zhang, Rui[33] ; Wang, Liping[34] ; Zhu, Youcai[35] ; Hu, Xiao[36] ; Xie, Yanru[37] ; Lin, Xinqing[26] ; Cai, Jing[11] ; Lan, Fen[10] ; Feng, Huijing[28] ; Wang, Lin[38] ; Yao, Wang[39] ; Shi, Xuefei[40] ; Huang, Jianhui[37] ; Chen, Huafei[35] ; Zhang, Yinbin[41] ; Sun, Pingli[42] ; Wan, Bing[43] ; Pang, Fei[44] ; Xu, Zanmei[44] ; Wang, Kai[44] ; Xia, Yuanli[45] ; Ye, Mingxiang[4] ; Wang, Dong[4] ; Wei, Qing[1] ; Feng, Shuitu[46] ; Zhou, Jianya[47] ; Zhang, Jiexia[26] ; Lv, Donglai[48] ; Gao, Wenbin[49] ; Kang, Jing[50] ; Yu, Genhua[51] ; Liang, Xianbin[52] ; Yu, Chengtao[53] ; Shi, Lin[54] ; Yang, Nong[6] ; Wu, Lin[19,20] ; Hong, Zhuan[55] ; Hong, Wei[1] ; Fang, Meiyu[1] ; Zhang, Yiping[1] ; Lu, Yuanzhi[56] ; Wang, Guansong[57] ; Ma, Shenglin[58] ; Si, Lu[9] ; Fang, Wenfeng[59] ; Song, Yong[4] ;
单位： [1]Chinese Acad Sci Univ Canc Hosp, Dept Chemotherapy, Zhejiang Canc Hosp, Hangzhou, Peoples R China [2]Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Resp Med, Affiliated Hosp, Nanjing, Peoples R China [3]Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou, Peoples R China [4]Nanjing Univ, Affiliated Jinling Hosp, Dept Resp Med, Med Sch, Nanjing 210002, Jiangsu, Peoples R China [5]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, Shanghai, Peoples R China [6]Cent South Univ, Dept Med Oncol,Xiangya Sch Med, Lung Canc & Gastrointestinal Unit, Hunan Canc Hosp,Affiliated Canc Hosp, Changsha, Peoples R China [7]Sun Yet Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept VIP Inpatient, State Key Lab Oncol South China, Guangzhou, Peoples R China [8]Zhejiang Univ, Translat Med Res Ctr, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Affiliated Hangzhou Peoples Hosp 1,Canc Ctr, Hangzhou, Peoples R China [9]Peking Univ Canc Hosp & Inst, Dept Melanoma & Sarcoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China [10]Zhejiang Univ, Key Lab Resp Dis Zhejiang Prov, Dept Resp & Crit Care Med, Affiliated Hosp 2,Sch Med,Canc Ctr, Hangzhou, Peoples R China [11]Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Peoples R China [12]Nanjing Univ, Dept Resp Med, Affiliated Drum Tower Hosp, Med Sch, Nanjing, Peoples R China [13]Yangzhou Univ, Subei Peoples Hosp Jiangsu Prov, Dept Resp Med, Clin Med Sch, Yangzhou, Jiangsu, Peoples R China [14]Fujian Med Univ Canc Hosp, Dept Med Oncol, Fuzhou, Peoples R China [15]Fujian Canc Hosp, Fuzhou, Peoples R China [16]Wuhan Univ, Dept Pathol, Renmin Hosp, Wuhan, Peoples R China [17]Nanjing Univ, Affiliated Jinling Hosp, Canc Ctr PLA, Dept Internal Med,Med Sch,Qinhuai Med Area, Nanjing, Peoples R China [18]Tianjin Med Univ Canc Inst & Hosp, Dept Integrat Oncol, Tianjin, Peoples R China [19]Cent South Univ, Dept Med Oncol, Lung Canc, Xiangya Sch Med, Changsha, Peoples R China [20]Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp, Changsha, Peoples R China [21]Univ Chinese Acad Sci, Hwamei Hosp, Dept Radiotherapy & Chemotherapy, Ningbo, Peoples R China [22]Wenzhou Med Univ, Dept Pulm Med, Taizhou Hosp, Taizhou, Peoples R China [23]Fujian Med Univ, Hosp 900, Dept Resp Med, Joint Logist Team,Fuzhou Gen Hosp, Fuzhou, Peoples R China [24]Capital Med Univ, Beijing Tiantan Hosp, Dept Oncol, Beijing, Peoples R China [25]Peking Univ Int Hosp, Dept Med Oncol, Beijing, Peoples R China [26]Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou, Peoples R China [27]Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Wenzhou, Peoples R China [28]Shanxi Acad Med Sci, Shanxi Bethune Hosp, Dept Thorac Oncol, Taiyuan, Peoples R China [29]Xi An Jiao Tong Univ, Dept Med Oncol, Affiliated Hosp 1, Xian, Peoples R China [30]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China [31]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China [32]Xiamen Univ, Affiliated Hosp Med 1, Dept Med Oncol, Xiamen, Peoples R China [33]China Med Univ, Dept Med Oncol, Canc Hosp, Shenyang, Peoples R China [34]Baotou Canc Hosp, Dept Oncol, Baotou, Peoples R China [35]Jiaxing Univ, Affiliated Hosp 3, Zhejiang Rongjun Hosp, Dept Thorac Dis,Diag & Treatment Ctr, Jiaxing, Peoples R China [36]Univ Chinese Acad Sci, Zhejiang Key Lab Radiat Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China [37]Lishui Municipal Cent Hosp, Dept Oncol, Lishui, Peoples R China [38]Shanxi Acad Med Sci, Shanxi Bethune Hosp, Dept Pathol, Taiyuan, Peoples R China [39]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Oncol, Guangzhou, Peoples R China [40]Zhejiang Univ, Huzhou Hosp, Dept Resp Med, Sch Med, Huzhou, Peoples R China [41]Xi An Jiao Tong Univ, Med Coll, Dept Oncol, Affiliated Hosp 2, Xian, Peoples R China [42]Second Hosp Jilin Univ, Dept Pathol, Changchun, Peoples R China [43]Nanjing Med Univ, Dept Resp Med, Affiliated Jiangning Hosp, Nanjing, Peoples R China [44]Shanghai OrigiMed Co Ltd, Dept Med, Shanghai, Peoples R China [45]AstraZeneca China, Dept Med Affairs, Shanghai, Peoples R China [46]Xiamen Haicang Hosp, Dept Oncol, Xiamen, Peoples R China [47]Zhejiang Univ, Affiliated Hosp 1, Thorac Dis Ctr, Sch Med, Hangzhou, Peoples R China [48]Joint Logist Support Force People Liberat Army, Dept Clin Oncol, Hosp 901, Hefei, Peoples R China [49]Shenzhen Univ, Dept Oncol, Affiliated Hosp 3, Shenzhen, Peoples R China [50]Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Lab Translat Med Lung Canc, Guangdong Prov Peoples Hosp,Sch Med, Guangzhou, Peoples R China [51]Zhebei Mingzhou Hosp, Dept Radiat Oncol, Huzhou, Peoples R China [52]Third Peoples Hosp Zhengzhou, Dept Oncol, Zhengzhou, Peoples R China [53]Collaborat Innovat Ctr Jiangsu Prov Canc Prevent, Nanjing, Peoples R China [54]Fudan Univ, Zhongshan Hosp, Dept Resp Med, Shanghai, Peoples R China [55]Nanjing Med Univ, Jiangsu Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Nanjing, Peoples R China [56]Jinan Univ, Dept Clin Pathol, Affiliated Hosp 1, Guangzhou, Peoples R China [57]Third Mil Med Univ, Xinqiao Hosp, Inst Resp Dis, Chongqing, Peoples R China [58]Zhejiang Univ, Sch Med, Canc Ctr,Key Lab Clin Canc Pharmacol & Toxicol Re, Affiliated Hangzhou Canc Hosp,Dept Oncol, Hangzhou, Peoples R China [59]Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
出处：
DOI： 10.1111/1759-7714.14693
ISSN：

关键词： checkpoint inhibitor pneumonitis Chinese experts consensus immune checkpoint inhibitor-related adverse effects

摘要：
Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
最新[2025]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
JCR分区：
出版当年[2020]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY
最新[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者单位： [1]Chinese Acad Sci Univ Canc Hosp, Dept Chemotherapy, Zhejiang Canc Hosp, Hangzhou, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Wenxian,Wang Qian,Xu Chunwei,et al.Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor[J].THORACIC CANCER.2022,13(23):3420-3430.doi:10.1111/1759-7714.14693.
APA：
Wang, Wenxian,Wang, Qian,Xu, Chunwei,Li, Ziming,Song, Zhengbo...&Song, Yong.(2022).Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.THORACIC CANCER,13,(23)
MLA：
Wang, Wenxian,et al."Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor".THORACIC CANCER 13..23(2022):3420-3430

相关文献

[1]Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer [2]Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis [3]Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019 [4]二甲双胍临床应用专家共识 [5]中国前列腺癌外科治疗专家共识 [6]老年人慢性心力衰竭诊治中国专家共识(2021) [7]主动脉夹层诊断与治疗规范中国专家共识 [8]阿尔茨海默病MR检查规范中国专家共识 [9]血液病分子生物学诊断技术中国专家共识（2013年版） [10]胸部恶性肿瘤围术期静脉血栓栓塞症预防中国专家共识(2018版)

资源点击量：586 今日访问量：0 总访问量：441 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）